Images List Premium Download Classic

Allergic Rhinitis

Allergic Rhinitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Pyrazolopyrimidine compounds
October 12, 2017 - N°20170290910

Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be ...
Compounds as crth2 antagonist and uses thereof
Sunshine Lake Pharma Co., Ltd.
September 21, 2017 - N°20170267634

The compounds of formula (i) which can be used as crth2 receptor antagonists are provided. The compounds of formula (i) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin d2 (pgd2) at the crth2 receptor.
Composition for the prevention and/or treatment of allergy symptoms
Ntc S.r.l.
September 14, 2017 - N°20170258864

The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract ...
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Phenyloxadiazole derivatives as pgds inhibitors
Oculeve, Inc.
August 17, 2017 - N°20170231990

Wherein r1, r2 and r3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma, chronic obstructive pulmonary disease (copd) and age-related macular degeneration (amd).
Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis
Bio.lo.ga. S.r.l.
June 15, 2017 - N°20170165226

Disclosed is a composition for topical application, for use in the prevention and treatment of allergic rhinitis it consists of an ester of alpha-tocopherol selected from the group consisting of tocopheryl acetate, n-propionate and linoleate, and an oily vehicle selected from the group consisting of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated ...
Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
Hanmi Pharm. Co., Ltd.
June 08, 2017 - N°20170157108

The present invention relates to a liquid formulation comprising a solubilizer and montelukast or pharmaceutically acceptable salt thereof in a solution state as an active ingredient, and a method for preparing same. The liquid formulation of the present invention allows montelukast or pharmaceutically acceptable salt thereof to be substantially dissolved and present in a solution state, thereby preventing decrease of ...
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
Academia Sinica
May 04, 2017 - N°20170121425

A novel humanized anti-ige antibody is disclosed. The antibody is capable of binding to free ige, membrane-bound ige on b lymphocytes, ige bound by cd23, but not to ige bound by high-affinity ige. Fc receptor on mast cells. The present invention relates to the treatment of ige-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) ...
Novel compounds
Academia Sinica
March 23, 2017 - N°20170080085

Wherein r1 is n-c4-6alkyl or c1-2alkoxyc1-2alkyl-; r2 is hydrogen or methyl; each r3 is hydroxy, halo or n-c1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds ...
New pyrazolyl-substituted heteroaryls and their use as medicaments
Academia Sinica
March 16, 2017 - N°20170073333

And the use of these aforementioned compounds for the treatment of diseases such as asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
Academia Sinica
March 02, 2017 - N°20170057963

Wherein r1 is hydrogen, methyl or —(ch2)2or3, r2 is methyl or —(ch2)2or4, or r1 and r2, together with the nitrogen atom to which they are attached, are linked to form a 5- or 6-membered heterocyclyl wherein the 6-membered heterocyclyl is optionally substituted by two hydroxy substituents; r3 and r4 are each independently hydrogen or methyl; and ...
Trk-inhibiting compound
Ono Pharmaceutical Co., Ltd.
February 02, 2017 - N°20170027939

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the ...
Oral controlled release pharmaceutical compositions of bepotastine
Lupin Limited
February 02, 2017 - N°20170027863

The present invention relates to oral controlled release pharmaceutical compositions comprising bepotastine. The oral controlled release pharmaceutical composition comprises bepotastine or pharmaceutically acceptable salts thereof and at least one release controlling agent. The present invention also provides the use of oral controlled release pharmaceutical compositions of bepotastine for the treatment of allergic rhinitis and for the treatment of pruritus caused ...
Heteroaryl syk inhibitors
Boehringer Ingelheim International Gmbh
January 12, 2017 - N°20170008896

The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each ...
Allergic Rhinitis Patent Pack
Download + patent application PDFs
Allergic Rhinitis Patent Applications
Download + Allergic Rhinitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Allergic Rhinitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Ionic aqueous compositions
Gerolymatos International S.a.
January 05, 2017 - N°20170000817

Disclosed herein are ionic aqueous compositions useful as nasal passage washes to aid in the resorption of edema of the respiratory mucosa, e. G., the nasal mucosa, for the treatment of respiratory tract and/or respiratory mucosal-related conditions, including, e. G., chronic rhinosinusitis, sinusitis, allergic rhinitis and nasal polyps. The composition includes an ionic aqueous solution and algae-derived constituents, such ...
Use of egg yolk oil and the benzopyrene-eliminated egg yolk oil in the treatment of ...
Harbin Medical University
December 22, 2016 - N°20160367604

The application of egg yolk oil, as well as benzopyrene-eliminated egg yolk oil, is prepared for medicaments for the treatment of allergic rhinitis. By topical application of egg yolk oil in the nasal cavity, symptoms of allergic rhinitis could be improved significantly. After topical treatment with egg yolk oil, levels of inflammatory cytokines il-4 and ige antibodies in lymphocytes of ...
Materials for treating and preventing mucosa related disease
Aihol Corporation
December 15, 2016 - N°20160361347

Provided is a hyaluronic acid (ha) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of has having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders ...
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Aihol Corporation
December 15, 2016 - N°20160361295

Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.
Pharmaceutical composition including dead cells of lactobacillus acidophilus lb to treat or prevent allergic disease
Aihol Corporation
November 10, 2016 - N°20160324906

Disclosed is a pharmaceutical composition including dead cells of lactobacillus acidophilus lb strain as an active ingredient for treating or preventing an allergic disease, and may be used to treat and prevent ige-mediated allergic diseases and non-ige-mediated allergic diseases such as atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, and pollinosis by reducing the total content of ige in the blood.
Human antibody molecules for il-13
Medimmune Limited
September 29, 2016 - N°20160280779

Specific binding members, in particular human anti-il-13 antibody molecules and especially those which neutralize il-13 activity. Methods for using anti-il-13 antibody molecules in diagnosis or treatment of il-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and hodgkin's lymphoma.
Trk-inhibiting compound
Ono Pharmaceutical Co., Ltd.
September 29, 2016 - N°20160280684

The present invention provides a drug containing a compound having trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or chagas disease. A compound represented by the general formula (i), wherein all symbols represent the same meanings as described in the ...
Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"
September 29, 2016 - N°20160279114

The present invention relates to novel biologically active glutarimide derivatives of general formula (i) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, churg-strauss syndrome, anaphylactic shock, quincke's edema, eosinophilic vasculitis, ...
Loading